Marcus Treviño

Reagent price per reaction ignores dead volume, lysate variability, and template prep costs.

Cell-free systems let researchers produce toxic proteins without harming a living host.

Cell-free synthesis overcomes structural barriers that kill bispecific antibody fragment production.

Cell-free synthesis beats E. coli for toxic proteins but loses on cost at scale.

Continuous exchange format extends reaction time to boost eukaryotic protein yields tenfold.

Reagent failure costs hidden in labor, delays, and bad data dwarf the price of prevention.

Choosing the right pricing model determines how many variants a lab can screen.

Cell-free protein synthesis delivers functional assays in hours instead of days.